[go: up one dir, main page]

MX2019009271A - Portador de sustancia fisiologicamente activa. - Google Patents

Portador de sustancia fisiologicamente activa.

Info

Publication number
MX2019009271A
MX2019009271A MX2019009271A MX2019009271A MX2019009271A MX 2019009271 A MX2019009271 A MX 2019009271A MX 2019009271 A MX2019009271 A MX 2019009271A MX 2019009271 A MX2019009271 A MX 2019009271A MX 2019009271 A MX2019009271 A MX 2019009271A
Authority
MX
Mexico
Prior art keywords
active substance
physiologically active
substance carrier
bioactive substance
silica particles
Prior art date
Application number
MX2019009271A
Other languages
English (en)
Other versions
MX388358B (es
Inventor
Won Cheolhee
Original Assignee
Lemonex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lemonex Inc filed Critical Lemonex Inc
Priority claimed from PCT/KR2018/001617 external-priority patent/WO2018143787A1/ko
Publication of MX2019009271A publication Critical patent/MX2019009271A/es
Publication of MX388358B publication Critical patent/MX388358B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B33/00—Silicon; Compounds thereof
    • C01B33/113—Silicon oxides; Hydrates thereof
    • C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B33/00—Silicon; Compounds thereof
    • C01B33/113—Silicon oxides; Hydrates thereof
    • C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid
    • C01B33/124—Preparation of adsorbing porous silica not in gel form and not finely divided, i.e. silicon skeletons, by acidic treatment of siliceous materials
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B33/00—Silicon; Compounds thereof
    • C01B33/113—Silicon oxides; Hydrates thereof
    • C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid
    • C01B33/18—Preparation of finely divided silica neither in sol nor in gel form; After-treatment thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/30—Particle morphology extending in three dimensions
    • C01P2004/32—Spheres
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/62—Submicrometer sized, i.e. from 0.1-1 micrometer
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/12—Surface area

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Silicon Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un portador de sustancia bioactiva, que incluye: una sustancia bioactiva; y partículas de sílice porosas que soportan la sustancia bioactiva y que tienen una pluralidad de poros con un diámetro de 5 nm a 100 nm, en donde las partículas de sílice porosas tienen propiedades físicas particulares, pueden administrar todos los diversos fármacos en una cantidad soportada de manera sostenida, y pueden ser administrado por vía parenteral.
MX2019009271A 2017-02-06 2018-02-06 Portador de sustancia fisiologicamente activa. MX388358B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455148P 2017-02-06 2017-02-06
PCT/KR2018/001617 WO2018143787A1 (ko) 2017-02-06 2018-02-06 생리활성물질 전달체
KR1020180014842A KR20180091768A (ko) 2017-02-06 2018-02-06 생리활성물질 전달체

Publications (2)

Publication Number Publication Date
MX2019009271A true MX2019009271A (es) 2019-10-30
MX388358B MX388358B (es) 2025-03-19

Family

ID=63443663

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009271A MX388358B (es) 2017-02-06 2018-02-06 Portador de sustancia fisiologicamente activa.

Country Status (11)

Country Link
US (4) US11129796B2 (es)
EP (1) EP3578171A4 (es)
JP (2) JP6883354B2 (es)
KR (1) KR20180091768A (es)
CN (2) CN110475546A (es)
AU (2) AU2018216591B2 (es)
BR (1) BR112019016281A2 (es)
CA (1) CA3052561C (es)
MX (1) MX388358B (es)
PH (1) PH12019550145A1 (es)
SG (1) SG11201907260PA (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115607688A (zh) 2014-07-22 2023-01-17 雷莫内克斯生物制药有限公司 用于递送生物活性物质或蛋白质的组合物及其用途
EP3578171A4 (en) 2017-02-06 2020-12-30 Lemonex Inc. PHYSIOLOGICALLY ACTIVE SUBSTANCE CARRIER
US20200163885A1 (en) * 2017-07-25 2020-05-28 Lemonex Inc. Composition for delivering physiologically active ingredients into blood vessel
KR102152348B1 (ko) * 2017-09-05 2020-09-08 주식회사 레모넥스 세포 운명 조절용 조성물
WO2020027571A1 (ko) * 2018-07-31 2020-02-06 주식회사 레모넥스 상처 치료용 의약 조성물
SG11202101258VA (en) 2018-08-06 2021-03-30 Lemonex Inc Immunoreactant carrier
WO2020032366A1 (ko) * 2018-08-06 2020-02-13 주식회사 레모넥스 면역반응 물질 전달체
WO2020202950A1 (ja) * 2019-03-29 2020-10-08 住友化学株式会社 無機多孔質担体及びこれを用いた核酸の製造方法
CN113631265A (zh) * 2019-03-29 2021-11-09 住友化学株式会社 无机多孔质担载体、及使用其的核酸的制造方法
CN113677432B (zh) 2019-03-29 2024-06-07 住友化学株式会社 无机多孔质担载体、及使用其的核酸的制造方法
WO2022005268A1 (ko) 2020-07-03 2022-01-06 주식회사 레모넥스 Rna 및 이를 포함하는 핵산 전달체
CN113189329A (zh) * 2020-10-14 2021-07-30 北京化工大学 一种基于单原子纳米酶的多重免疫比色病毒检测方法
US20240261390A1 (en) * 2021-05-28 2024-08-08 Lemonex Inc. Vaccine for prevention or treatment of viral infection
JPWO2023149227A1 (es) * 2022-02-03 2023-08-10
CN115337306B (zh) * 2022-09-20 2023-10-20 河南大学 甲磺酸二氢麦角碱靶向stat3在制备抗炎性疾病和抗肿瘤药物中的应用
CN116920003B (zh) * 2023-08-29 2024-06-07 河北瑞龙生物科技有限公司 一种从月见草中提取总黄酮的方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
WO2006128121A2 (en) 2005-05-27 2006-11-30 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
WO2008021908A2 (en) 2006-08-08 2008-02-21 Board Of Regents Of The University Of Texas Multistage delivery of active agents
US9993437B2 (en) 2007-12-06 2018-06-12 The Regents Of The University Of California Mesoporous silica nanoparticles for biomedical applications
KR100950548B1 (ko) * 2008-01-10 2010-03-30 연세대학교 산학협력단 다공성 중공 실리카 나노입자, 그의 제조 방법, 상기를포함하는 약물 전달체 및 약제학적 조성물
US8012508B2 (en) 2008-01-15 2011-09-06 Abbott Cardiovascular Systems Inc. Method of targeting sustained release formulations of therapeutic agents to treat lung diseases
KR101569227B1 (ko) 2008-03-11 2015-11-13 아스카 세이야쿠 가부시키가이샤 고체 분산체와 그 의약 조성물, 그리고 그들의 제조 방법
KR101057116B1 (ko) 2008-06-17 2011-08-16 한국과학기술원 포유류에서의 분화 조절제 및 분화 조절 방법
US8252337B2 (en) 2008-10-23 2012-08-28 National Health Research Institutes Charged mesoporous silica nanoparticle-based drug delivery system for controlled release and enhanced bioavailability
KR101137886B1 (ko) 2009-04-24 2012-04-25 조선대학교산학협력단 다공성 실리콘 입자를 이용한 영상진단 약물전달체 및 그의 제조방법
KR101087262B1 (ko) 2009-06-26 2011-11-29 한국외국어대학교 연구산학협력단 중공형 메조다공성 실리카 캡슐 및 그 제조방법
FR2952368B1 (fr) 2009-11-10 2012-01-13 Commissariat Energie Atomique Particule de silice incorporant une molecule d'interet, son procede de preparation et ses utilisations.
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
US20110256184A1 (en) 2010-04-14 2011-10-20 Battelle Memorial Institute Non-ordered Mesoporous Silica Structure for Biomolecule Loading and Release
KR20120025224A (ko) 2010-09-07 2012-03-15 인하대학교 산학협력단 다공성 실리카 나노입자 및 사이클로덱스트린을 포함하는 약물전달체
CA2834365A1 (en) 2011-04-28 2012-11-01 Sandia Corporation Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
BR112014008932A2 (pt) 2011-10-14 2019-09-24 Sandia Corp bicamadas lipídicas suportadas em nanopartículas porosas (protocélulas) para administração direcionada, incluindo a administração transdérmica de uma carga e métodos associados
US20140014327A1 (en) 2012-07-13 2014-01-16 Schlumberger Technology Corporation Methodology and system for producing fluids from a condensate gas reservoir
KR101388958B1 (ko) 2012-07-16 2014-04-24 서울대학교산학협력단 약물전달용 조성물 및 이를 이용한 약물전달방법
KR101528197B1 (ko) 2013-07-29 2015-06-15 서강대학교산학협력단 ｐＨ-반응성 키토산-코팅 다공성 실리카 나노입자
CN103751857A (zh) 2014-01-22 2014-04-30 同济大学 一种载药二氧化硅栓塞微球及其制备方法
CN115607688A (zh) 2014-07-22 2023-01-17 雷莫内克斯生物制药有限公司 用于递送生物活性物质或蛋白质的组合物及其用途
CN105560186A (zh) * 2014-10-13 2016-05-11 卫生部北京医院 一种治疗心脏病的缓释药物制剂
ES2993458T3 (en) 2015-03-16 2024-12-30 Pdx Pharmaceuticals Inc Cross-linked polymer modified nanoparticles
KR101724142B1 (ko) 2015-05-22 2017-04-18 차의과학대학교 산학협력단 약물 전달용 조성물, 그 제조방법, 및 이를 이용한 약물 전달 방법
CA2990247C (en) 2015-07-09 2023-10-03 The Regents Of The University Of California Fusogenic liposome-coated porous silicon nanoparticles
US11420986B2 (en) 2015-11-02 2022-08-23 The University Of North Carolina At Chapel Hill Functionalized mesoporous silica via an aminosilane surfactant ion exchange reaction: controlled scaffold design and nitric oxide release
CN105456198B (zh) * 2015-12-25 2017-04-26 正大天晴药业集团股份有限公司 一种荷载恩替卡韦介孔二氧化硅纳米粒及其制备方法
KR101924519B1 (ko) 2016-06-08 2018-12-04 광주과학기술원 펩타이드-키토산 개질 나노입자 및 이를 포함하는 약물 전달체
KR101754798B1 (ko) 2016-07-28 2017-07-06 한국과학기술원 사이토카인이 담지된 다공성 실리카 나노입자를 포함하는 m2 대식세포로의 분화유도용 조성물
KR101762825B1 (ko) 2016-08-08 2017-07-28 한국과학기술원 사이토카인이 담지된 다공성 실리카 나노입자를 포함하는 염증억제용 조성물
EP3578171A4 (en) * 2017-02-06 2020-12-30 Lemonex Inc. PHYSIOLOGICALLY ACTIVE SUBSTANCE CARRIER
US20200163885A1 (en) 2017-07-25 2020-05-28 Lemonex Inc. Composition for delivering physiologically active ingredients into blood vessel

Also Published As

Publication number Publication date
JP6883354B2 (ja) 2021-06-09
US20200009054A1 (en) 2020-01-09
US20250032414A1 (en) 2025-01-30
US20210369614A1 (en) 2021-12-02
JP2020506972A (ja) 2020-03-05
BR112019016281A2 (pt) 2020-04-14
CN110475546A (zh) 2019-11-19
AU2021232725B2 (en) 2023-07-20
CA3052561A1 (en) 2018-08-09
US11129796B2 (en) 2021-09-28
US12138346B2 (en) 2024-11-12
PH12019550145A1 (en) 2020-06-08
CA3052561C (en) 2023-02-14
EP3578171A1 (en) 2019-12-11
EP3578171A4 (en) 2020-12-30
CN119564881A (zh) 2025-03-07
US11793757B2 (en) 2023-10-24
JP7360727B2 (ja) 2023-10-13
AU2021232725A1 (en) 2021-10-14
MX388358B (es) 2025-03-19
JP2021143177A (ja) 2021-09-24
KR20180091768A (ko) 2018-08-16
AU2018216591A1 (en) 2019-08-29
SG11201907260PA (en) 2019-09-27
AU2018216591B2 (en) 2021-07-22
US20240041771A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
MX2019009271A (es) Portador de sustancia fisiologicamente activa.
MX2020003661A (es) Formas de dosificacion de liquidos, metodos de fabricacion y uso.
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
WO2017091749A8 (en) Shape changing drug delivery devices and methods
MX379193B (es) Composiciones en solucion solida y su uso en inflamacion cronica.
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
BR112015018092A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
BR112015018094A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112015018087A8 (pt) composto, composição farmacêutica e uso
UY31543A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
CL2015002835A1 (es) Nuevos derivados de piridina
CL2009001077A1 (es) Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo.
CR20110267A (es) Tratamiento de transtornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo[]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
UY29186A1 (es) Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)
DOP2015000071A (es) Fármaco combinado que comprende gemigliptina y metformina, y método para su preparación
CL2009000322A1 (es) Composicion farmaceutica que comprende flibanserina en su forma amorfa y al menos un excipiente, sistema farmaceutico de liberacion que comprende esta composicion, metodo para fabricar este sistema y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, trastornos del sueño y sexuales, entre otros.
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
MX386476B (es) Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo.
NI201000181A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona.
CO2019012428A2 (es) Composición líquida de suspensión de esmectita y método de preparación de la misma
CL2012003209A1 (es) Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico.
SV2011003919A (es) Extrudidos con sustancias activas con forma de agujas
ES2652253T3 (es) Preparación de vitamina